ICHIRO ABE. Efficacy and safety of low-dose ipragliflozin, a selective sodium glucose transporter 2 inhibitor, in patients with type 2 diabetes mellitus. International Journal of Allied Medical Sciences and Clinical Research, [S. l.], v. 4, n. 3, p. 376–382, 2020. DOI: 10.61096/ijamscr.v4.iss3.2016.376-382. Disponível em: https://ijamscr.com/ijamscr/article/view/283. Acesso em: 29 apr. 2024.